Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

DPP4 in anti-tumor immunity: going beyond the enzyme

Nature Immunology volume 16, pages 791–792 (2015)Cite this article

Subjects

Effective anti-tumor immune therapy in solid tumors relies on the presence of effector T cells. Inhibition of the dipeptidylpeptidase DPP4 (CD26) enhances chemokine CXCL10–mediated infiltration of lymphocytes into the tumor parenchyma, which results in diminished tumor growth.

Access through your institution
Buy or subscribe

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Access through your institution

Buy this article

  • Purchase on SpringerLink
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Inhibition of DPP4 suppresses truncation of its ligand CXCL10, which leads to the recruitment of CXCR3+ T cells into tumor parenchyma.

Marina Corral Spence/Nature Publishing Group

References

  1. Ohnuma, K., Dang, N.H. & Morimoto, C. Trends Immunol. 29, 295–301 (2008).

    Article  CAS  Google Scholar 

  2. Barreira da Silva, R. et al. Nat. Immunol. 16, 850–858 (2015).

    Article  CAS  Google Scholar 

  3. van der Bruggen, P. et al. Science 254, 1643–1647 (1991).

    Article  CAS  Google Scholar 

  4. Liu, M., Guo, S. & Stiles, J.K. Oncol. Lett. 2, 583–589 (2011).

    Article  CAS  Google Scholar 

  5. Groom, J.R. & Luster, A.D. Exp. Cell Res. 317, 620–631 (2011).

    Article  CAS  Google Scholar 

  6. Koch, M.A. et al. Nat. Immunol. 10, 595–602 (2009).

    Article  CAS  Google Scholar 

  7. Shi, Z. et al. Eur. J. Immunol. 39, 2106–2119 (2009).

    Article  CAS  Google Scholar 

  8. Davies, S., Beckenkamp, A. & Buffon, A. Biomed. Pharmacother. 71, 135–138 (2015).

    Article  CAS  Google Scholar 

  9. Herrmann, H. et al. Blood 123, 3951–3962 (2014).

    Article  CAS  Google Scholar 

  10. Havre, P.A. et al. Front. Biosci. 13, 1634–1645 (2008).

    Article  CAS  Google Scholar 

  11. Hatano, R. et al. J. Immunol. 194, 960–972 (2015).

    Article  CAS  Google Scholar 

  12. Nguyen, L.T. & Ohashi, P.S. Nat. Rev. Immunol. 15, 45–56 (2015).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Ryo Hatano and Chikao Morimoto are in the Department of Therapy Development and Innovation for Immune Disorders and Cancers, Kei Ohnuma, Graduate School of Medicine, Juntendo University, Tokyo, Japan.,

    Kei Ohnuma, Ryo Hatano & Chikao Morimoto

Authors
  1. Kei Ohnuma
    View author publications

    You can also search for this author inPubMed Google Scholar

  2. Ryo Hatano
    View author publications

    You can also search for this author inPubMed Google Scholar

  3. Chikao Morimoto
    View author publications

    You can also search for this author inPubMed Google Scholar

Corresponding author

Correspondence to Chikao Morimoto.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ohnuma, K., Hatano, R. & Morimoto, C. DPP4 in anti-tumor immunity: going beyond the enzyme. Nat Immunol 16, 791–792 (2015). https://doi.org/10.1038/ni.3210

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ni.3210

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer